Skip to main content
. 2020 Jan 25;2020(1):CD012501. doi: 10.1002/14651858.CD012501.pub2

Wada 1996.

Methods 4‐week washout period
8‐week before‐and‐after study
Participants 19 men and women with type IIa and IIb hyperlipidaemia age ≥ 20 years
TC ≥ 220 mg/dL (5.69 mmol/L)
Exclusion criteria: statin hypersensitivity, hypothyroidism, Cushing's syndrome, obstructive gallbladder disease, SLE, nephrosis, HDL seborrhoea, drug‐induced hyperlipidaemia, diet therapy for obesity, secondary hyperlipidaemia, alcohol abuse
Cerivastatin 0.15 mg/d baseline TC: 6.90 mmol/L (267 mg/dL)
Interventions Cerivastatin 0.15 mg/d evening dosing
Outcomes Percentage change from baseline at 4‐8 weeks of blood TC
Source of funding Unknown
Notes LDL‐C, HDL‐C and TG were not included in the efficacy analysis because the given values and the calculated values differed by > 10%
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) High risk Controlled before‐and‐after design
Allocation concealment (selection bias) High risk Controlled before‐and‐after design
Blinding of participants and personnel (performance bias) 
 All outcomes Low risk Lipid parameter measurements unlikely influenced by lack of blinding
Blinding of outcome assessment (detection bias) 
 LDL‐C Low risk Lipid parameters were measured in a remote laboratory
Blinding of outcome assessment (detection bias) 
 WDAE High risk No comparison possible
Incomplete outcome data (attrition bias) 
 Total cholesterol Low risk [(19‐18)/19)*100 = 5.3% participants were not included in the efficacy analysis
Incomplete outcome data (attrition bias) 
 LDL cholesterol High risk Excluded because was not included in the efficacy analysis because the given values and the calculated values differed by > 10%
Incomplete outcome data (attrition bias) 
 HDL cholesterol High risk Excluded because was not included in the efficacy analysis because the given values and the calculated values differed by > 10%
Incomplete outcome data (attrition bias) 
 Triglycerides High risk Excluded because was not included in the efficacy analysis because the given values and the calculated values differed by > 10%
Selective reporting (reporting bias) High risk LDL‐C outcome was not reported
Other bias Unclear risk Source of funding not reported